Questions without answers Theralase says the FDA defined a complete clinical dataset on approx 20 to 25 patients enrolled, treated and assessed who demonstrate significant safety and efficacy outcomes for BTD.
With 24 patients completed why is the company waiting months for 1 more patient? Regardless of the last scan result 1433 will exceed the Keytruda results at 450 days.
It looks like 4 patients were treated in the last three months.
As of May 30th we had a CR of 17 and PR of 8 and at the end of Aug a CR of 19 and PR of 6 for scans at 90 days. There were 4 scans pending May 30th so what happened to those patients; N/R, or no scans done? Trying to understand the results isn't easy when the company continues to change their results tables.
The company has 12 sites in operation although up to 15 were contemplated as part of the trial study. Will they expand to 15? Have all sites treated patients? This trial is taking forever to complete and we are only 35% of the way through treating 120 patients.
The management notes provide no guidance as to the company's capital requirements in 2023. There really is no discussion of the vaccine opportunity outside of the current Covid animal testing. While the company has executed the SRA with UM where does the company see this opportunity going in 2023 and beyond?
I think the company is sitting on some great technology but the stock is at $0.30/share...